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Abstract Alterations in metal ion homeostasis
appear coupled to neurodegenerative disorders but
mechanisms are unknown. Amyloid formation of the
protein a-synuclein in brain cells is a hallmark of
Parkinson’s disease. a-Synuclein can bind several
metal ions in vitro and such interactions may affect the
assembly process. Here we used biophysical methods
to study the effects of micromolar concentrations of
Cu2? and Fe3? ions on amyloid formation of selected
a-synuclein variants (wild-type and A53T a-synu-
clein, in normal and N-terminally acetylated forms).
As shown previously, Cu2? speeds up aggregation of
normal wild-type a-synuclein, but not the acetylated
form. However, Cu2? has a minimal effect on (the
faster) aggregation of normal A53T a-synuclein,
despite that Cu2? binds to this variant. Like Cu2?,
Fe3? speeds up aggregation of non-acetylated wild-
type a-synuclein, but with acetylation, Fe3? instead
slows down aggregation. In contrast, for A53T a-
synuclein, regardless of acetylation, Fe3? slows down
aggregation with the effect being most dramatic for
acetylated A53T a-synuclein. The results presented
here suggest a correlation between metal-ion modu-
lation effect and intrinsic aggregation speed of the
various a-synuclein variants.
Keywords a-Synuclein  Parkinson’s disease 
Metal ions  Acetylation  Thioflavin T  Amyloid
formation
Introduction
A unifying molecular event in neurodegenerative
disorders is the aberrant self-assembly of proteins into
amyloid fibers with a hallmark cross-b-sheet arrange-
ment. Parkinson’s disease (PD) is the second most
common neurodegenerative disorder (after Alzhei-
mer’s disease) and the most common movement
disorder. PD is characterized by widespread deterio-
ration of subcortical structures of the brain, especially
dopaminergic neurons in the substantia nigra (Chen
et al. 2014). Conformational changes resulting in
aggregation of the intrinsically-disordered protein a-
synuclein (aSyn) into amyloid fibers is directly related
to PD (Winner et al. 2011; Galvin et al. 1999). Many
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amyloidogenic proteins (including aSyn) can bind
metals in vitro and systemic as well as tissue
imbalances of metal levels are often found to be
strongly associated with neurodegenerative disorders
including PD (Fink 2006). This implies that metal ions
may play pivotal roles in progression of PD and other
neurodegenerative disorders (Bush 2000; Bjorklund
et al. 2019; Aaseth et al. 2018). Notably, the brain has
a high demand for metal ions and, as such, it can
viewed as an organ that concentrates metal ions (Bush
2000; Valiente-Gabioud et al. 2012).
For PD, it has been found that copper levels are
decreased in brain tissue but increased in fluids,
whereas for iron, the levels are increased in brain cells
(Bush 2000). The differences noted vary between
brain regions (Bjorklund et al. 2019; Aaseth et al.
2018). Also other metal ion levels are altered in PD
and, for example, occupational exposure to high
manganese levels have been linked to Parkinsonism,
a disorder similar to PD (Bjorklund et al. 2019; Aaseth
et al. 2018). Of metal ions interacting with aSyn,
copper ions display the strongest affinity (nanomolar
range) (Binolfi et al. 2010). Copper (Cu) in both redox
states (oxidized = Cu2?; reduced = Cu?) can bind to
aSyn (Camponeschi et al. 2013; De Ricco et al. 2015a)
and structural features, binding sites, and affinities for
the interaction between aSyn and Cu2?, as well as
Cu?, have been the focus of many in vitro spectro-
scopic investigations (Camponeschi et al. 2013; De
Ricco et al. 2015a; Binolfi et al. 2006, 2011; Carboni
and Lingor 2015). Whereas the high affinity Cu2? site
involves backbone nitrogen atoms in residues Met1
and Asp2, the dominant Cu? binding site involves the
side chain sulfurs of Met1 and Met5 (Moriarty et al.
2014a; Miotto et al. 2015). Also iron in both redox
states (oxidized = Fe3?; reduced = Fe2?) can bind to
aSyn but with micromolar affinity [differs between
redox states, and between published reports (Peng
et al. 2010; Davies et al. 2011a)] and the aSyn
interaction site involves residues 119 to 124 (119-
DPDNEA124) in the C-terminal part (Abeyawardhane
and Lucas 2019). Many metal ions can accelerate
aSyn amyloid formation, but Cu2? has the largest such
effect in vitro (Montes et al. 2014; Davies et al. 2016).
However, parallel comparisons of metal-ion effects on
aSyn aggregation, at biologically-relevant metal ion
concentrations and for biologically-relevant aSyn
variants (such as with N-terminal acetylation), are
lacking.
Although biological systems are complex and many
factors must be taken into consideration (e.g., redox
reactions, protein partners, local concentrations, mem-
branes) to understand PD development in patients
(Bush 2000; Bjorklund et al. 2019; Aaseth et al. 2018),
it is of fundamental importance to reveal intrinsic
features of how metal ions affect aSyn amyloid
formation. Here we compared the effects of Cu2? and
Fe3? on aSyn amyloid formation, using micromolar
concentrations of metal ions and a set of PD-relevant
aSyn variants, in vitro. The obtained results demon-
strate a dependency among metal ion identity, con-
centration and aSyn variant that appears related to
differential aSyn monomer conformation and thereby
intrinsic aggregation speed.
Materials and methods
Expression and purification of aSyn variants
Human WT and A53T aSyn proteins in non-acetylated
forms were expressed heterologously in Escherichia
coli as reported in Werner et al. (2018). In short,
plasmids for WT and A53T aSyn were transformed
into BL21 (DE3) (Novagen) cells. The bacteria were
first grown to an OD600 of 0.6 in Luria broth (LB)
containing 100 lg/ml carbenicillin at 37 C and then
induced with 1 mM IPTG (isopropyl b-D-1–thiogalac-
topyranoside) and grown overnight at 25 C post
induction. The cells were harvested and lysed by
sonication on an ice bath in 20 mM Tris–HCl buffer
pH 8.0 in the presence of protease inhibitor cocktail
(Roche). The lysate after sonication was treated with a
universal nuclease (Pierce) for 15 min at room tem-
perature. The lysate was then heat treated at 90 C in a
water bath for 10 min followed by centrifugation at
15,000 9 g for 30 min. The supernatant was then
filtered through 0.2 lm filter and loaded on to a pre-
equilibrated 5 ml HiTrap Q FF anion exchange
column (GE Healthcare). The aSyn proteins were
eluted by a linear gradient with 1 M NaCl in 20 mM
Tris–HCl buffer pH 8.0. The eluted protein were run
on a 4–12% SDS-PAGE and fractions containing the
protein of interest were pooled and concentrated with
Amicon Ultra-15 10 K centrifugal filter units (Milli-
pore). The concentrated protein was loaded and
retrieved from a pre-equilibrated Hiload 16/600
Superdex 75 pg column (GE Healthcare) with
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20 mM Tris–sulfate buffer pH 7.4. For all purified
aSyn variants, the sample purity was confirmed by a
single band on SDS-PAGE gel, a single elution peak in
size exclusion chromatography, and by mass spec-
trometry. Fractions containing pure protein were
pooled and snap frozen in liquid nitrogen and stored
at - 80 C. The concentration of WT and A53T aSyn
was determined using e280 = 5960 M
-1 cm-1. Acety-
lated WT and A53T aSyn proteins were overexpressed
by co-transforming the pT7-7 aSyn plasmid with
pNatB (a kind gift of D. P. Mulvihill) (Johnson et al.
2013), expressing the yeast N-acetyl-transferase NatB
gene. After expression, the protein purification proce-
dure was exactly the same as for the non-acetylated
aSyn variants, see above. The co-expression process
resulted in the isolation of fully amino-terminal
acetylated aSyn protein, which was confirmed by
mass spectrometry.
As described earlier (Horvath et al. 2018), prepa-
ration of (non-acetylated) truncated aSyn (residues
1–97) used a pET3a construct (including a tag with a
repressor protein and a His-stretch followed by a
Caspase 7 cleavage site) with the gene for truncated
aSyn. The plasmid was transformed into BL21(DE3)
(Novagen) cells, which were then grown in similar
conditions as for WT aSyn. The cells were harvested
by centrifugation and re-suspended in Buffer A
(20 mM Tris–HCl pH 8, 20 mM imidazole and 8 M
urea), then sonicated and centrifuged for 30 min at
15,0009g. The supernatant was filtered through a
0.2 lm filter and applied to a 5 ml Hi Trap Ni–NTA
column (GE healthcare) pre-equilibrated with Buffer
A. After washing the column with 5 column volumes
of buffer B (20 mM Tris–sulfate pH 7.4, 20 mM
imidazole, 50 mM NaCl), truncated aSyn was eluted
with buffer B, with added 250 mM imidazole. The tag
was cleaved upon addition of Caspase 7 in the ratio of
1:100 (caspase 7: truncated aS w/w) in the presence of
5 mM TCEP (tris (2-carboxyethyl) phosphine) and
incubated overnight at 4 C. The protein was checked
for cleavage and dialyzed overnight to remove excess
imidazole. The cleaved protein was loaded onto a
5 mL HiTrap Q FF anion exchange column (GE
Healthcare) and eluted by a linear gradient of 1 M
NaCl in 20 mM Tris–HCl buffer, pH 8.0. The eluted
fractions were pooled, concentrated and loaded onto a
Hiload 16/600 Superdex 75 column (GE Healthcare).
The protein was eluted in 20 mM Tris–HCl buffer pH
7.4. Fractions containing aSyn were pooled, snap
frozen in liquid nitrogen and stored in -80 C.
ThT aggregation assay
aSyn amyloid formation reactions were conducted in
96-well half-area transparent bottom plates with a
non-binding surface (Corning, CLS3881) with one
2-mm glass bead in each well using a plate reader-
incubator instrument (BMG Labtech, Fluostar
Optima). The plates were sealed with transparent tape
to prevent evaporation and contamination. Measure-
ments performed in TBS (0.05 M Tris–HCl buffer, pH
7.4 with 0.15 M NaCl, 93318 Sigma-Aldrich) buffer
in the presence of 20 lM Thioflavin T (ThT, T3516
Sigma-Aldrich) at 37 C using 200 rpm agitation for
5 min during the 20 min measurement cycles, fluo-
rescence was measured from the bottom side of the
plate. All aSyn samples were gel filtered prior to
aggregation experiments in order to ensure the starting
point is only monomers. In all aggregation measure-
ments, the aSyn concentration was 50 lM. Samples
were typically incubated for 60 h and fluorescence
measured every 20 min. ThT was excited at 440 nm
and emission was recorded at 480 nm. All ThT
experiments were performed in quadruplicates at each
time, and repeated at least three independent times.
For seeded ThT aggregation experiments (in which
elongation dominate the kinetics) of WT aSyn as a
function of Fe3?, preformed aSyn amyloids were
added (5 lM monomer concentration) to fresh aSyn
monomers (50 lM) and aggregation experiments, as
above, were started.
Atomic force microscopy (AFM)
Aggregated samples from ThT experiments were
diluted into MilliQ water (10–20 times) and deposited
on freshly cleaved mica. After 10 min, the mica was
rinsed with filtered Milli-Q water and dried under a
gentle nitrogen stream. Images were recorded on an
NTEGRA Prima setup (NT-MDT) using a gold-coated
single crystal silicon cantilever (NT-MDT, NSG01,
spring constant of * 5.1 N/m) and a resonance
frequency of * 180 kHz. 256 pixel images were
acquired with 0.5 Hz scan rate. Images were analyzed
using the WSxM 5.0 software (Horcas et al. 2007). For
each sample images were collected in at least three
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different 50 9 50 lm areas, the images shown are
representative for each sample.
Transmission electron microscopy (TEM)
The samples were taken from the incubation mixture
from the ThT-aggregation assays after 60–100 h (the
samples were considered to be at the end of fibril
formation stage), in the presence and absence of metal
ions. The samples were placed on glow-charged,
formvar coated, carbon-stabilized copper EM
grids. Absorption of sample lasted 2 min, followed
by staining with 1 percent aqueous phosphotungstate
(1% PTA). The grids were then blotted with filter
paper and dried before use (Choi et al. 2018). High
contrast images were obtained with a TALOS L120C
TEM at an accelerating voltage of 120 kV, using a
4 9 4 k CMOS Ceta camera. The magnification was
set to 17,5009–3000009.
Circular dichroism (CD)
CD was measured in the near-UV region
(250–700 nm) on Jasco J-810 and Chirascan-CS
spectrophotometers using a 1-cm quartz cuvette at
20 8C. Protein samples (ca 100–150 lM aSyn in the
same TBS buffer as in aggregation experiments) were
titrated with Cu2?, going from 1:0.25 to 1:2 protein:Cu
ratios, with approximately 10 min incubation between
each addition. Each experiment was repeated three
times. The CD data was normalized to mean residue
ellipticity.
Results
We monitored, using the thioflavin T (ThT) fluores-
cence assay, the kinetics of aggregation of selected
aSyn variants (50 lM) as a function of Cu2? and Fe3?
ions (in the range 0–400 lM) at pH 7, 37 C under
agitation with a glass bead. Agitation in combination
with a glass bead is used to increase the reproducibility
of the kinetic data (Giehm et al. 2011). The presence of
only aSyn monomers at the starting point was ensured
by performing gel filtration chromatography of the
samples directly prior to each aggregation experiment.
As it is now established that aSyn is acetylated at the
N-terminal amino group in vivo (Bartels et al. 2011),
we here focused on wild-type (WT) and Ala53Thr
(A53T; early onset PD-causing mutation) (Poly-
meropoulos et al. 1997; Kruger et al. 1998) aSyn
variants in both non-acetylated and acetylated states.
The acetylated aSyn variants were prepared using an
established procedure (Johnson et al. 2013) and
modification of the resulting protein was confirmed
by mass spectrometry. Representative kinetic aggre-
gation curves for the four proteins alone and upon
additions of the metal ions are shown in Figures S1–
S3.
Effect of Cu ions on amyloid formation of aSyn
variants
As expected (Moriarty et al. 2014a; Montes et al.
2014; Davies et al. 2016), we found Cu2? to promote
aggregation of non-acetylated WT aSyn in a concen-
tration dependent manner but these metal ions had no
effect on aggregation kinetics of acetylated WT aSyn
(Figs. 1, S2). Surprisingly, for non-acetylated A53T
aSyn, Cu2? had no effects on the kinetics of aggre-
gation, although the mutation is not involving Cu-
binding residues. In similarity with acetylated WT
aSyn, and reflecting lack of the high affinity binding
site, aggregation of acetylated A53T aSyn was not
affected by Cu2? additions.
To assure that Cu2? binds to A53T aSyn at our
conditions, despite the lack of effect on aggregation
kinetics, we turned to near-UV circular dichroism
spectroscopy (CD). Cu2? binding to the N-terminal
Cu2? site in aSyn can be detected via a negative CD
signal around 300 nm (charge transfer transition from
metal center to an imidazole group or deprotonated
peptide nitrogen) and a positive CD signal at 600 nm
(d–d transition) (Binolfi et al. 2006, 2010; Rasia et al.
2005). In Fig. 2, we show that non-acetylated A53T
aSyn binds Cu2?, in an apparent similar coordination
to WT aSyn (Binolfi et al. 2010), but none of the two
acetylated variants bind Cu2?. Thus, Cu2? binds
efficiently to A53T aSyn but this interaction does not
affect aggregation kinetics. To test if the lack of Cu2?
effect on aggregation relates to intrinsic speed of
aggregation, as A53T aSyn aggregates faster than WT
aSyn, we investigated truncated aSyn (contains only
residues 1–97) that aggregates even faster than A53T
aSyn. The CD and ThT data in Fig. S4 demonstrate
that truncated aSyn interacts with Cu2? like WT and
A53T aSyn, but (in similarity to A53T aSyn) this
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interaction has no effect on aggregation kinetics of
truncated aSyn.
Effect of Fe ions on amyloid formation of aSyn
variants
Like Cu2?, Fe3? speeds up aggregation of non-
acetylated WT aSyn, but with acetylation, Fe3?
additions gives a complex trend (Figs. 1, S3). At low
Fe3? concentration (25, 50 lM), aggregation of aSyn
becomes faster whereas at higher Fe3? concentration
(200 and 400 lM) metal binding slows down aggre-
gation of aSyn. In contrast, for A53T aSyn, regardless
of acetylation or not, for all concentrations, Fe3? slows
down aggregation with the effect being most dramatic
for the acetylated form of A53T aSyn (Figs. 1, S3). We
note that Fe3? has a tendency to precipitate in pH-
neutral solutions (Peng et al. 2010) and we checked on
this carefully. At our conditions and incubation times,
like in other studies (Abeyawardhane et al. 2018),
there was no precipitation of Fe3? detected. In
addition, as a control, we tested the effect of Fe3?
ions on the aggregation reaction of truncated aSyn. As
the binding site for Fe3? is suggested to be in the
C-terminus (Joppe et al. 2019), Fe3? should not affect
aggregation of truncated aSyn—unless artifacts were
at play. In Figure S5, we show that Fe3? has no effect
on truncated aSyn aggregation kinetics. This result
supports that modulation of aggregation kinetics of
WT and A53T aSyn upon Fe3? additions are conse-
quences of metal binding to the protein.
Fig. 1 Midpoints of aggregation curves (derived from ThT-
detected kinetic data; Figures S2–S3) for various additions of
Fe3? (red) and Cu2? (blue) to aSyn variants: a WT aSyn.
b Acetylated WT aSyn. c A53T aSyn. d Acetylated A53T aSyn.
Significance scale according to: *p\ 0.05, **p\ 0.01,
***p\ 0.001. The p values were obtained by the Student’s
t test method. The shown data is based on three independent
experiments with four replica in each. Midpoints are defined as
the time when the ThT signal has reached 50% of its final value
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Fig. 2 Near-UV CD spectra
for aSyn variants upon
addition of Cu2? as
indicated. a Acetylated WT
aSyn. b A53T aSyn.
c Acetylated A53T aSyn
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By the use of seeded aSyn aggregation experi-
ments, where the fiber elongation process dominates,
one can assess if an inhibitory effect is due to blockage
of amyloid fiber elongation or not (Meisl et al. 2016).
Seeding of the aggregation reaction of acetylated WT
aSyn (using 10% amyloid seeds) speeds up aggrega-
tion, as expected. When Fe3? was added to such
seeded reactions, the metal ions had no effect on aSyn
aggregation kinetics (Figure S6). Thus, Fe3?-mediated
inhibition of amyloid formation of acetylated aSyn is
not due to effects on elongation but appears linked to
nucleation steps (primary or secondary nucleation).
For all the aSyn aggregation reactions in the
presence of metal ions, we checked the resulting
amyloid fibers by AFM or TEM at the end of the
aggregation experiments (Figure S7). In all cases,
including the ones where fiber formation was delayed,
amyloids are formed and there are no striking differ-
ences in amyloid fiber appearances (for this resolu-
tion) without and with added metal ions.
Discussion
To eventually counteract neurodegenerative diseases,
we must gain better knowledge of metal-ion interac-
tions that may modulate amyloid formation. Interest-
ingly, aSyn, which aggregates into amyloid fibers in
PD, is annotated in uniprot.org as copper-binding and
it can also bind other metal ions in vitro (Montes et al.
2014; Davies et al. 2016). Progressive increase of
metal ion content in brain tissue is thought to be a
consequence of normal aging and may be one factor
promoting age-related neurodegeneration (Valiente-
Gabioud et al. 2012). Also prolonged exposure to e.g.
iron, manganese and copper via external sources (such
as industrial work exposure) increases the risk for PD
and other neurodegenerative diseases (Bjorklund et al.
2019; Aaseth et al. 2018; Valiente-Gabioud et al.
2012). In brain biopsies from PD patients, iron levels
are elevated while cellular copper levels appear
reduced (Abeyawardhane and Lucas 2019). Nonethe-
less, extracellular copper levels at the synapse may
reach high micromolar concentrations (Kardos et al.
1989) and for PD patients, copper is elevated in serum
(Bush 2000). Because iron and copper dys-homeosta-
sis appears directly related to PD, and both metal ions
bind to aSyn in vitro, we here compared the effects of
micromolar concentrations of Cu2? and Fe3? on the
in vitro aggregation of selected, biologically-relevant
aSyn variants. Our results may act as a biophysical
starting point for more advanced investigations taking
biological aspects into account. Although there has
been previous reports of the effects of these metal ions
on aSyn aggregation, the two ions have not been
compared in parallel nor have the consequences of
aSyn mutation and acetylation been addressed in
combination with these metal ions.
In accord with several reports, we found Cu2? to
accelerate non-acetylated WT aSyn aggregation
(Montes et al. 2014; Davies et al. 2016; Uversky
et al. 2001) whereas with acetylation, the reaction was
not affected by Cu2? (Moriarty et al. 2014b; Mason
et al. 2016). Surprisingly, for A53T aSyn, regardless
of acetylation or not, Cu2? additions did not affect
aggregation kinetics although our CD experiments, as
expected, showed that Cu2? binds to non-acetylated
A53T aSyn like it does to WT aSyn. For the acetylated
forms, WT and A53T aSyn, no CD signals appeared
upon Cu2? additions, indicative of lack of metal-ion
binding. Acetylation blocks the N-terminal high-
affinity Cu2? site, but His50 (and C-terminal residues
with weak affinity to Cu2?) remains a putative Cu2?-
binding site. However, if Cu2? would bind around
His50, such an interaction should give rise to a CD
signal (Tian et al. 2019) and thus we conclude that for
our acetylated aSyn variants at our conditions, the
affinity of Cu2? must be less than 100 lM. That Cu2?
binding does not affect aggregation kinetics of non-
acetylated A53T aSyn may be related to the intrinsi-
cally faster aggregation speed of this variant (Fig-
ure S1). The faster aggregation speed of A53T aSyn
(as compared to WT) has been linked to fewer long-
range contacts in the mutant’s monomeric state
(Bertoncini et al. 2005). Thus, Cu2? binding to WT
aSyn may change the monomer conformation towards
that of A53T aSyn, with the consequence of faster
aggregation (Fig. 3). For A53T aSyn, already in a
more extended conformation, Cu2? binding may not
affect the conformational landscape of the monomer
further, and thus Cu2? binding does not affect kinetics
of aggregation. In accord with this reasoning, for
truncated aSyn, that aggregates even faster than A53T
aSyn, Cu2? binding had no effect on the aggregation
kinetics (Figure S4).
It has been reported that millimolar Fe3? speeds up
non-acetylated WT aSyn aggregation (Uversky et al.
2001) but the effect of Fe3? on aggregation kinetics of
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acetylated aSyn has not been tested. One study tested
the effects of Fe3? and Fe2? on resulting amyloid fiber
structures of acetylated WT aSyn, but no kinetics were
reported (Abeyawardhane et al. 2018). Our data show
that when probed in the micromolar range, Fe3?
accelerates aggregation of non-acetylated WT aSyn,
but for acetylated WT and A53T aSyn (with and
without acetylation) the effect of Fe3? is to slow down
the aggregation kinetics. We rationalize this by
differences in conformations of the monomeric vari-
ants that, in turn, relate to intrinsic aggregation speeds.
As mentioned, A53T aggregates faster than WT aSyn
(Figure S1). When WT aSyn is acetylated, it aggre-
gates faster, but acetylation does not matter much for
intrinsic aggregation speed of A53T aSyn (Figure S1).
While the A53T aSyn variant has less long-range
contacts (Bertoncini et al. 2005), N-terminal aSyn
acetylation results in increased local helical content
(Kang et al. 2012). Both these alterations thus allows
for faster aggregation kinetics, with the mutation
having the largest effect. Therefore, we speculate that
Fe3? binding to non-acetylated WT aSyn alters the
monomer conformation towards that of the mutant
(i.e., more extended structure) and this speeds up
Fig. 3 Scheme illustrating the link between metal effects and
intrinsic aSyn variant aggregation speed (monomer conforma-
tion). a Aggregation-promoting effect of Cu2? is only found
when intrinsic aggregation is slow, as for WT aSyn. For A53T
and truncated (1–97) aSyn, which both aggregates faster, Cu2?
has no accelerating effect. b Aggregation-modulating effect of
Fe3? depends on intrinsic aggregation speed. Whereas WT aSyn
is accelerated by Fe3?, the faster aggregating variants acetylated
WT aSyn, A53T aSyn and acetylated A53T are instead slowed
down by Fe3?. The intrinsic aSyn aggregation speed of variants
can be linked to their individual monomer conformational
landscape, with WT aSyn being more compacted (involving
inhibitory interactions between N- and C-termini) than A53T
aSyn and acetylation results in transient helicity in the
N-terminal part (see text)
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aggregation. In contrast, for acetylated WT and both
forms of A53T aSyn, Fe3? binding instead changes
the conformations (towards more compact forms) such
that aggregation becomes slower (illustrated in
Fig. 3).
In vivo, many factors, such as metal-induced redox
reactions (Abeyawardhane and Lucas 2019; Miotto
et al. 2014; Davies et al. 2011b) and metal-binding
proteins (Montes et al. 2014; McLeary et al. 2019),
have to be taken into account (Bush 2000). For
example, it was recently shown that, when bound to
aSyn, copper could cycle between oxidized and
reduced forms (Miotto et al. 2014; Davies et al.
2011b; Wang et al. 2010) and such copper-bound
aSyn was able to act as a ferri-reductase using the
copper ion as a catalytic redox center (Brown 2013; De
Ricco et al. 2015b). In another study, it was shown that
the copper transport protein Atox1, which transports
Cu? in the cytoplasm, could form a complex with
aSyn (regardless of acetylation) and this interaction
blocked aSyn aggregation (Horvath et al. 2019). It is
also possible that the resulting aSyn amyloid fibers,
and intermediate species (oligomers), differ in the
presence or absence of metal ions. One study showed
that in the presence of Cu2?, the formed aSyn amyloid
fibers appeared more neurotoxic than in the absence of
Cu2? (Choi et al. 2018). To resolve the connection
between metal ion metabolism and neurodegenera-
tion, many additional studies, spanning from bio-
physics in vitro (as here) to cellular models and living
systems, are desired.
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